The co-administration of HSP90 and the agonist led to an augmented HSP90-specific CD8+ response and significantly prolonged the survival time of breast-cancer-bearing mice compared to the mice that received monotherapy of HSP90 and the agonist [181]. Here, CD8A is linked to breast cancer.